期刊文献+

PPARγ在阿尔茨海默病中的作用及影响因素研究进展 被引量:3

The role of PPARγ in Alzheimer's disease and its impact factors
下载PDF
导出
摘要 阿尔茨海默症(Alzheimer's disease,AD)是一种以记忆丧失和认知衰退为主要临床症状的大脑神经退行性疾病。目前有关AD的病因仍然不明确且临床上无有效的防治措施。PPARγ是一种配体激活型转录因子,在AD的病理过程中扮演着重要角色,可作为神经保护作用靶点;同时许多PPARγ的激动剂己经被证明在AD的细胞和动物模型上具有神经保护作用。文中综述了PPARγ在AD中发挥的作用,以及影响PPARγ活化的因素,特别强调矢车菊素-3-O-葡糖糖苷(Cy3G)在发挥神经保护作用的同时,可能作为神经系统中潜在的PPARγ激动剂。 Alzheimer's disease (AD), is a neurodegenerative disorder of the brain that is characterized by loss of memory and cognitive decline. At present, AD etiology remains unclear and there are no effective prevention and treatment measures in clinical practice. Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-regulated nuclear hormone receptor. Recent studies showed PPARγ -pathway played an important role in the pathogenesis of AD and some PPARγ agonists have been proven to be neuroproteetive in vitro and in vivo models. This paper reviews the roles of PPARγ and related mechanisms in AD, summarizes affecting factors about PPARγ pathway. Particularly, the effect of cyanidin-3-O-glucoside (Cy3G), one of the anthocyanidin glycoside forms, is a compound of naturally occurring phenolic compounds, suggesting the neuroprotective effect of Cy3G might be used as a potential natural PPARγ agonist in the nervous system.
作者 宋楠 秦川
出处 《医学研究生学报》 CAS 北大核心 2015年第9期989-994,共6页 Journal of Medical Postgraduates
基金 国家高技术研究发展计划863项目(2013AA020106) 国家科技重大专项课题(2012ZX10004501)
关键词 PPARΓ PPARΓ激动剂 基因表达调控 神经保护 Cy3G PPARγ PPARγ agonist Gene expression regulation Neuroprotection Cy3 G
  • 相关文献

参考文献48

  • 1Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and ther- apeutic strategies[ J ]. Prog Neurobiol, 2013, 108 : 21-43.
  • 2王晓妮,唐毅,韩璎.阿尔茨海默病诊断标准的演变[J].医学研究生学报,2015,28(2):195-198. 被引量:24
  • 3Krishnan K J, Ratnaike TE, De Gruyter HL, et al. Mitochondrial DNA deletions cause the biochemical defect observed in Alzhei- mer's disease I J]. Neurobiol Aging, 2012, 33 (9): 2210-2214.
  • 4Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease[ J]. Nature, 2000, 405 (6785) : 421-424. Sugii S, Evans RM. Epigenetic codes of PPAR-/ in metabolic disease[ J]. FEBS Lett, 2011, 585 ( 13 ) : 2121-2128.
  • 5蔡辉.过氧化物酶体增殖激活物受体γ与动脉粥样硬化的研究进展[J].医学研究生学报,2011,24(10):99-102. 被引量:2
  • 6Benedusi V, Martorana F, Brambilla L, et al. The peroxisome proliferator-activated receptor -/ (PPAR-,) controls natural pro- tective mechanisms against lipid peroxidation in amyotrophic lat- eral sclerosis [ J ]. J Biol Chem, 2012,287 (43) : 35899 -35911.
  • 7Sastre M, Dewachter I, Rossner S, et al. Nonsteroidal anti-in- flammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma [ J ]. Proc Natl Acad Sci USA, 2006, 103(2): 443-448.
  • 8Quintanilla RA, Utreras E, Cabezas-Opazo FA. Role of PPAR in the differentiation and function of neurons [ J -. PPAR Res, 2014, 768594.
  • 9Alzheimer's Association. 2014 Alzheimer's disease facts and fig- ures[J]. Alzheimers Dement, 2014, 10(2): e47-92.
  • 10Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms un- derlying the rapid peroxisome proliferator-activated receptor--- mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease[ J]. J Neurosci, 2012, 32 (30) : 10117-10128.

二级参考文献34

  • 1A. T. Gonon MD, PhD,A. Bulhak,F. Labruto,P.-O. Sj?quist,J. Pernow.Cardioprotection mediated by rosiglitazone, a peroxisome proliferatoractivated receptor gamma ligand, in relation to nitric oxide[J],2007.
  • 2Adamiec R,Gacka M,Dobosz T,et al.Stimulation of the peroxi-some proliferators activated receptor gamma and the expression ofselected blood monocyte cytokine genes in diabetic macroangiopa-thyAtherosclerosis,2007.
  • 3Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking patho- physiological processes in Alzheimer's disease: an updated hypo- thetical modal of dynamic biomarkers[J]. Lancet Neurol, 2013, 12(2) : 207-216.
  • 4Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study [J]. Lancet Neurol, 2013, 12(4): 357-367.
  • 5Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer' s disease: academic, industry and regulatory perspectives [ J]. Nat Rev Drug Discov, 2010, 9(7) : 560-574.
  • 6Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage [ J ]. Sci Transl Med, 2011, 3 (111): 111 end3.
  • 7McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzhcimcr's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer' s disease [ J ]. Neurology, 1984, 34(7) : 939-944.
  • 8Dubois B, Feldman HH, Jaeova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADR- DA criteria[J]. Lancet Neurol, 2007, 6(8) : 734-746.
  • 9Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer' s disease : a new lexicon [ J ]. Lancet Neurol, 2010, 9(11) : 1118-1127.
  • 10Sperling RA, Aisen PS, Beekett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association work- groups on diagnostic guidelines for Alzheimer' s disease [ J ]. Alzheimers Dement, 2011, 7 ( 3 ) : 280-292.

共引文献24

同被引文献41

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部